162 related articles for article (PubMed ID: 35422411)
1. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse.
Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):151-153. PubMed ID: 36699422
[TBL] [Abstract][Full Text] [Related]
3. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
[TBL] [Abstract][Full Text] [Related]
4. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
5. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].
Yuan RF; Dong YJ; Li CR; Huang WR; Zhang LM; Zhu Q; Xu L; Xu YJ; Xu Q; Gao GX; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):10-15. PubMed ID: 32023748
[No Abstract] [Full Text] [Related]
7. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
[TBL] [Abstract][Full Text] [Related]
8. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
[No Abstract] [Full Text] [Related]
10. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.
Mei J; Zhai Y; Li H; Li F; Zhou X; Song P; Zhao Q; Yu Y; An Z; Wang L
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2263-2273. PubMed ID: 30167888
[TBL] [Abstract][Full Text] [Related]
12. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
14. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
15. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
16. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
Jung HA; Jang MA; Kim K; Kim SH
Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
[TBL] [Abstract][Full Text] [Related]
18. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
20. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
